Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for BioGend Therapeutics Co's Debt-to-EBITDA or its related term are showing as below:
ROCO:6733'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.14 Med: -0.12 Max: -0.04
Current: -0.14
During the past 10 years, the highest Debt-to-EBITDA Ratio of BioGend Therapeutics Co was -0.04. The lowest was -0.14. And the median was -0.12.
ROCO:6733's Debt-to-EBITDA is ranked worse than 100% of 318
companies
in the Biotechnology industry
Industry Median: 1.27
vs ROCO:6733: -0.14
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
BioGend Therapeutics Co Debt-to-EBITDA Related Terms
BioGend Therapeutics Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6733 vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, BioGend Therapeutics Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGend Therapeutics Co Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioGend Therapeutics Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BioGend Therapeutics Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
BioGend Therapeutics Co (ROCO:6733) has a Debt-to-EBITDA of -0.08 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on BioGend Therapeutics Co. According to the industry distribution chart, BioGend Therapeutics Co ranks #999999 out of 318 companies in the Biotechnology industry.
Is BioGend Therapeutics Co's Debt-to-EBITDA too high?
BioGend Therapeutics Co's current Debt-to-EBITDA is -0.08. Based on the distribution chart, BioGend Therapeutics Co ranks #999999 out of 318 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioGend Therapeutics Co has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioGend Therapeutics Co's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioGend Therapeutics Co ranks #999999 out of 318 companies for Debt-to-EBITDA. This places BioGend Therapeutics Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.27, based on 318 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on BioGend Therapeutics Co. For the Biotechnology industry, the median Debt-to-EBITDA is 1.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGend Therapeutics Co's current Debt-to-EBITDA is -0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGend Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, BioGend Therapeutics Co (ROCO:6733) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$51.37, compared to a current price of NT$25.85 — trading 49.7% below its estimated fair value. The current Debt-to-EBITDA is -0.08. BioGend Therapeutics Co's overall GF Score™ is 74/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For BioGend Therapeutics Co (ROCO:6733), the current Debt-to-EBITDA is -0.08 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGend Therapeutics Co (ROCO:6733) Overvalued in 2026?
Based on GuruFocus' analysis, BioGend Therapeutics Co stock appears to be undervalued.
The current stock price of NT$25.85 is trading 49.7% below its estimated GF Value™ of NT$51.37.
GuruFocus considers BioGend Therapeutics Co to be Significantly Undervalued.
Key valuation signals for ROCO:6733:
Debt-to-EBITDA: -0.08
GF Value™: NT$51.37 vs. price of NT$25.85 (49.7% below fair value)
No single metric tells the full story. See the ROCO:6733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGend Therapeutics Co Ltd is a Taiwan-based company involved in the research and development of orthopedic medical equipment and related products, and the sale of related products. It is involved in the research and development of inventive cartilage repair technology and products, adipose stem cell extraction technology, and others. Geographically, the company generates a majority of its revenue from Taiwan, followed by China, Malaysia, and other regions.
74GF Score
Get the complete analysis for ROCO:6733
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6733 has been successfully added to your 
